IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/309% above fair value
$31.83+0.34 (+1.08%)
Close on Nov 13, 2026Market cap $3.07BP/E –Yield –
IDEAYA Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
IDEAYA Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -74.8%. For fiscal 2025 it was -52.0%, against -3921.1% the year before. The highest annual figure on record is -52.0% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -52.0% | +3869.1 |
| FY2024 | Dec 31, 2024 | -3921.1% | −3438.1 |
| FY2023 | Dec 31, 2023 | -483.0% | −367.9 |
| FY2022 | Dec 31, 2022 | -115.2% | +62.9 |
| FY2021 | Dec 31, 2021 | -178.1% | −1.5 |
| FY2020 | Dec 31, 2020 | -176.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1269.6% | +592.0 |
| Q1 FY2026 | Mar 31, 2026 | -1502.1% | −636.4 |
| Q4 FY2025 | Dec 31, 2025 | -765.7% | −424.3 |
| Q3 FY2025 | Sep 30, 2025 | 57.4% | +845.4 |
| Q4 FY2024 | Dec 31, 2024 | -1861.6% | −1561.6 |
| Q4 FY2023 | Dec 31, 2023 | -865.8% | −264.0 |
| Q3 FY2023 | Sep 30, 2023 | -341.4% | −346.8 |
| Q2 FY2023 | Jun 30, 2023 | -788.0% | −411.0 |
| Q1 FY2023 | Mar 31, 2023 | -300.0% | −176.6 |
| Q4 FY2022 | Dec 31, 2022 | -601.7% | +13.1 |
| Q3 FY2022 | Sep 30, 2022 | 5.4% | +134.5 |
| Q2 FY2022 | Jun 30, 2022 | -377.0% | −251.9 |
| Q1 FY2022 | Mar 31, 2022 | -123.4% | +1.1 |
| Q4 FY2021 | Dec 31, 2021 | -614.9% | −566.3 |
| Q3 FY2021 | Sep 30, 2021 | -129.0% | −74.1 |
| Q2 FY2021 | Jun 30, 2021 | -125.0% | – |
| Q1 FY2021 | Mar 31, 2021 | -124.5% | – |
| Q4 FY2020 | Dec 31, 2020 | -48.6% | – |
| Q3 FY2020 | Sep 30, 2020 | -54.9% | – |
See a number that looks wrong?